Orser Capital Management’s AbbVie ABBV Stock Holding History

Orser Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,851	Closed	-$1.17M	–	43
2023 Q3	$1.17M	Hold	7,851	–	–	1.16%	32
2023 Q2	$1.06M	Hold	7,851	–	–	1.06%	35
2023 Q1	$1.25M	Hold	7,851	–	–	1.41%	23
2022 Q4	$1.27M	Hold	7,851	–	–	1.83%	20
2022 Q3	$1.05M	Hold	7,851	–	–	1.87%	18
2022 Q2	$1.2M	Hold	7,851	–	–	1.56%	23
2022 Q1	$1.27M	Hold	7,851	–	–	0.78%	40
2021 Q4	$1.06M	Hold	7,851	–	–	0.54%	53
2021 Q3	$847K	Hold	7,851	–	–	0.47%	57
2021 Q2	$884K	Hold	7,851	–	–	0.45%	61
2021 Q1	$850K	Hold	7,851	–	–	0.55%	56
2020 Q4	$841K	Buy	7,851 +180	+2%	+$17.3K	0.53%	54
2020 Q3	$672K	Hold	7,671	–	–	0.53%	49
2020 Q2	$753K	Hold	7,671	–	–	0.68%	36
2020 Q1	$584K	Hold	7,671	–	–	0.82%	28
2019 Q4	$679K	Buy	+7,671	New	+$637K	0.66%	44
2018 Q2	–	Sell	-3,661	Closed	-$365K	–	91
2018 Q1	$365K	Buy	+3,661	New	+$402K	0.34%	77

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Orser Capital Management's ABBV Position: Q4 2023 in Review

Orser Capital Management sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 7,851 shares — an estimated $1.17M sold.

Orser Capital Management first reported a position in ABBV in Q1 2018 and held it in 17 quarters. The position peaked at $1.27M in Q1 2022. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Orser Capital Management reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Orser Capital Management sold 7,851 AbbVie shares in Q4 2023, an estimated $1.17M.
Orser Capital Management first reported a position in AbbVie in Q1 2018 and held it in 17 quarters.
Orser Capital Management's AbbVie position peaked at $1.27M in Q1 2022.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Orser Capital Management's 13F filing for Q4 2023, filed 9 Jan 2024.